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Levetiracetam (LEV) is an anti-epileptic drug commonly used for the treatment of partial
onset and generalized seizures. In addition to its neuromodulatory and neuroinhibitory
effects via its binding to the synaptic vesicle protein SV2A, multiple studies have sug-
gested neuroprotective properties for LEV in both epileptic and non-epileptic conditions.
The purpose of this review is to discuss the extent of LEV-mediated protection seen in
different neurological conditions, the potential of LEV for easing epileptogenesis, and the
possible mechanisms that underlie the protective properties of LEV. LEV has been found to
be particularly beneficial for restraining seizures in animal models of spontaneous epilepsy,
acute seizures, and status epilepticus (SE). However, its ability for easing epileptogenesis
and cognitive dysfunction following SE remains controversial with some studies implying
favorable outcomes and others reporting no beneficial effects. Efficacy of LEV as a neu-
roprotective drug against traumatic brain injury (TBI) has received much attention. While
animal studies in TBI models have showed significant neuroprotection and improvements
in motor and memory performance with LEV treatment, clinical studies suggest that LEV
has similar efficacy as phenytoin in terms of its ability to prevent post-traumatic epilepsy.
LEV treatment for TBI is also reported to have fewer adverse effects and monitoring con-
siderations but electroencephalographic recordings suggest the presence of increased
seizure tendency. Studies on stroke imply that LEV is a useful alternative to carbamazepine
for preventing post-stroke seizures in terms of efficacy and safety. Thus, LEV treatment
has promise for restraining SE-, TBI-, or stroke-induced chronic epilepsy. Nevertheless,
additional studies are needed to ascertain the most apt dose, timing of intervention, and
duration of treatment after the initial precipitating injury and the mechanisms underlying
LEV-mediated beneficial effects.
Keywords: traumatic brain injury, stroke, acute seizures, chronic epilepsy, post-traumatic seizures, post-traumatic
epilepsy, neurodegeneration, epileptogenesis
INTRODUCTION
Levetiracetam [LEV; 2S-(oxo-1-pyrrolidinyl) butanamide] is an
anti-epileptic drug (AED) often utilized for the treatment of
partial onset and generalized seizures (1, 2). LEV has both anti-
seizure and anti-epileptogenic properties. It has been also pro-
posed that LEV is an attractive AED for managing post-traumatic
seizures (PTSs) owing to its beneficial pharmacokinetic attrib-
utes, including excellent bioavailability, linear kinetics, minimal
plasma protein binding, and rapid achievement of steady state
concentrations (2–4). The underlying mechanisms by which LEV
facilitates anti-epileptic and anti-epileptogenic effects are dif-
ferent from classic AEDs. Studies insinuate that LEV bestows
its effects mainly through the inhibition of the synaptic vesi-
cle protein 2A (1). Additional investigations have also revealed
that LEV can inhibit HVA-Ca2 channels (N-type), negate the
inhibition of negative allosteric modulators such as zinc and β-
carbolines of γ-aminobutyric acid (GABA)- and glycine-gated
currents, and diminish the calcium release from intraneuronal
stores (1, 5).
Moreover, a multitude of studies have proposed that LEV has
considerable neuroprotective properties in both epileptic and non-
epileptic disorders (2, 6–9). The capability of LEV to augment the
manifestation of glial glutamate transporters EAAT1/GLAST and
EAAT2/GLT-1 has been proposed as one of the foremost mecha-
nisms through which LEV mediates its neuroprotective properties
(2, 10). This hypothesis fits well with one of the conspicuous
changes detected following most brain insults, which is increased
concentration of glutamate in the extracellular areas causing
enhanced activation of N -methyl-d-aspartate (NMDA) recep-
tors and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptors on neurons and culminating in significant
neurodegeneration (2, 11, 12). The efficacy of LEV as a neuro-
protective compound has been examined in several brain injury
and neurodegenerative disease prototypes. These include brain

























































Shetty Levetiracetam and neuroprotection
damage resulting from status epilepticus (SE) or acute seizures,
spontaneous epilepsy, closed head trauma, subarachnoid hem-
orrhage (SAH), hypoxic-ischemia, and stroke. The goal of this
review is to confer the extent of LEV-mediated neuroprotection
observed in different brain injury models, the potential of LEV for
easing epileptogenesis, and the possible mechanisms that under-
lie neuroprotective properties of LEV in different neurological
conditions.
EFFICACY OF LEV FOR EASING SEIZURES AND
SEIZURE-MEDIATED NEURODEGENERATION
Levetiracetam administration appears to be beneficial for restrain-
ing seizures, and acute seizure or SE induced neurodegeneration
in animal models. A single dose of LEV administered 30 min after
the onset of behavioral SE was adequate for transiently attenuat-
ing seizure activity in animals treated with LEV at 800 mg/kg or
higher (13). Increased doses of LEV (1000 mg/kg or higher) damp-
ened behavioral seizures for prolonged periods. When admin-
istered early (i.e., 10 min) after the onset of SE, 400 mg/kg of
LEV transiently attenuated behavioral seizures and higher doses
dampened seizures for relatively longer periods. Pretreatment with
LEV prior to pilocarpine injection delayed the onset of seizures
but did not significantly alter ictal discharge measured through
electroencephalographic (EEG) recordings (13). Analyses with
TUNEL staining however demonstrated reduced neuronal injury
in the hippocampus and other limbic brain regions in animals that
responded behaviorally to LEV.
Levetiracetam treatment appears to mediate anti-seizure effects
through several mechanisms. A study using acute hippocampal
slices from spontaneously epileptic rats (SERs) have suggested that
LEV modulates Ca2+ currents in neurons, as application of 10µM
of LEV decreased the amplitude of the Ca2+ current in CA3 pyra-
midal neurons and application of 100 nM–1 mM of LEV reduced
the Ca2+ current in a concentration-dependent manner (14). LEV
also elevated the threshold potential level for activation of the Ca2+
current and reduced the L-type Ca2+ current in neurons. Fur-
thermore, LEV can abolish the SE-induced rise in brain-derived
neurotrophic factor, a neurotrophic factor believed to contribute
to seizures at higher concentrations. Moreover, administration
of LEV after SE can enhance levels of Y1- and Y5-like receptors
of neuropeptide Y (NPY; an endogenous anticonvulsant) in all
subfields of the hippocampus (15). Also, anti-epileptic effect of
LEV is apparent from a study in an animal model of hypoxia-
induced seizures (16). LEV pretreatment in postnatal day 10
rats significantly decreased the cumulative duration of hypoxia-
induced behavioral and electrographic seizures at 25 and 50 mg/kg
doses. Additionally, kainate-induced seizures and neuronal loss
were significantly diminished in postnatal day 40 rats previously
treated with LEV. Thus, LEV treatment can not only suppress
acute seizures but also diminish later-life seizure susceptibility and
seizure-induced neuronal injury. This suggests that LEV treatment
after injury or acute seizures has potential for disease modification.
A recent study has examined the neuroprotective property of
LEV against SE in greater detail (17) by administering the drug 2 h
after the onset of SE at 50, 100, or 150 mg/kg. Analyses through
staining for Fluoro-Jade B (a marker of degenerating neurons)
suggested that low dose administration of LEV (50 mg/kg) can
reduce SE-induced loss of CA1 pyramidal neurons and dentate
hilar neurons but not CA3 pyramidal neurons. However, LEV
treatment at a higher dose (100 mg/kg) reduced degenerating
neurons in CA1 and CA3 pyramidal cell layers as well as the den-
tate hilus. Furthermore, a much higher dose of LEV (150 mg/kg)
greatly reduced the numbers of degenerating neurons in the
CA3 pyramidal cell layer. Interestingly, when different doses of
LEV were combined with diazepam (10 mg/kg), neurodegenera-
tion was exacerbated in the hippocampus. Collectively, this study
demonstrated that LEV alone is more efficacious for preventing
SE-induced neurodegeneration in the hippocampus than other
AEDs such as diazepam or valproate (17). Furthermore, the find-
ing that combined administration of LEV and diazepam actually
increases neurodegeneration suggested that LEV negatively inter-
acts with diazepam, implying that LEV may be more suitable as a
first line drug to minimize SE-induced neurodegeneration rather
than as an add-on drug with benzodiazepines (17). Thus, LEV
administration after the onset of SE is beneficial for suppress-
ing seizures as well as reducing neurodegeneration. Mechanisms
of LEV-mediated neuroprotection likely include its anti-seizure
effects as well as its purported ability to decrease the expression
of pro-oxidant protein iNOS and increase the expression of the
antioxidant protein cystine/glutamate exchanger in the hippocam-
pus (18). A study in pilocarpine model of SE also showed that LEV
pretreatment could counteract oxidative stress through mainte-
nance of lipid peroxidation, nitrite-nitrate levels, catalase activity,
and glutathione at normal levels in the hippocampus (19).
USEFULNESS OF LEV FOR EASING EPILEPTOGENESIS
Prolonged LEV treatment after SE appears to delay or restrain the
development of chronic epilepsy in animal models. A study exam-
ined the effects of chronic LEV treatment on hippocampal field
responses in rats subjected to pilocarpine induced SE (20). Hip-
pocampal field potentials were recorded in vivo in anesthetized
animals after 3-day washout period that followed 21-day treat-
ment with different doses of LEV (50, 150, or 300 mg/kg/day)
administered via osmotic minipumps. Chronic treatment with
LEV yielded clinically relevant plasma concentrations throughout
the experiment with complete washout of the drug 3 days after
treatment cessation. At this point of time post-SE rats chronically
treated with vehicle developed clear signs of hippocampal hyper-
excitability typified by increased amplitude of population spike
(PS) recorded in the DG and reduced paired-pulse inhibition in
the CA1 area. LEV treatment dose-dependently counteracted these
long-term effects of SE. Furthermore, at the dose of 300 mg/kg/day,
LEV restored these parameters back to control levels (20). Several
other studies have also shown beneficial effects of LEV treatment
in acute seizure models. For example, the development of kin-
dling (a progressive increase in seizure severity induced by repeated
brain stimulation at certain intervals), and kindling-related abnor-
mal gene expression can be considerably modulated through daily
application of LEV (15, 21, 22).
Furthermore, LEV administration at 40 mg/kg is efficacious
not only for suppressing the development of kindling but also
for dampening kindling-induced expression of multiple immedi-
ate early genes (IEGs) including many synaptic plasticity-related
IEGs, and some late response genes encoding transcription factors,
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neurotrophic factors, and proteins that are known to regulate
synaptic remodeling (23). An additional potential mechanism by
which LEV suppresses the development of kindling is through
significant inhibition of kindling-induced synaptic potentiation
(24). LEV treatment after kindling can also prevent asymmetric
accumulation of hippocampal 7S SNARE complexes [the secre-
tory machinery responsible for neurotransmitter (NT) release]
and accumulation of SV2 (25). Thus, LEV treatment can ease mul-
tiple abnormalities induced by kindling at cellular and molecular
levels.
Moreover, a study in a kainate model of SE examining the long-
term effects of LEV treatment, commencing a day after the onset of
SE and continuing for 25 days (26) demonstrated that LEV treat-
ment after SE can decrease the mean duration of spontaneous
electrographic seizures in the chronic phase after SE. Interestingly,
LEV administration also greatly eased SE-induced aberrant migra-
tion of newly born neurons into the dentate hilus, an abnormal
process that is believed to contribute to the formation of aber-
rant hippocampal circuitry and epileptogenesis after SE (27, 28).
LEV administration has also been found to be effective for easing
inflammatory responses in the hippocampus and piriform cor-
tex of epileptic rats (29). These brain regions in epileptic animals
typically demonstrate reactive astrocytes and activated microglia
displaying strong expression of IL-1β and interleukin-1 receptor
subtype 1 (IL-1R1). Interestingly, LEV administration reduced
reactive gliosis and expression levels of IL-1β in both of these
brain regions. These findings suggested that LEV likely mediates its
anti-epileptogenic effects at least partially through modulation of
inflammation in epileptic brain regions. Studies in SERs have also
suggested anti-epileptogenic effects of LEV (30). Administration
of LEV (80 mg/kg/day) to SERs from postnatal weeks 5–8 signifi-
cantly inhibited seizures at postnatal weeks 5–13. It is of interest to
note that inhibition of seizure expression in SERs was still appar-
ent 5 weeks after the termination of LEV treatment, reinforcing
that LEV possesses anti-epileptogenic properties.
From the above studies, it is tempting to conclude that chronic
treatment with LEV is efficacious for restraining the evolution of
initial SE-induced brain insults into a state of hippocampal hyper-
excitability and chronic epilepsy. However, currently, there is no
clear consensus regarding anti-epileptogenic effects of LEV in SE
models. For instance, a study in amygdala kindling model of SE
showed that prophylactic treatment with LEV has no effect on
epileptogenesis, neuronal damage, or behavioral alterations in rats
(31). In one set of studies, LEV treatment was initiated 24 h after
onset of electrical amygdala stimulation without termination of SE
and continued for 8 weeks using osmotic minipumps. In another
set of studies, LEV treatment commenced 4 h after the onset of
SE with seizure termination through diazepam and continued for
5 weeks. Interestingly, with either treatment regimen, LEV did not
exert anti-epileptogenic or neuroprotective activity. Furthermore,
behavioral hyperexcitability and learning deficits were not affected
by treatment with LEV after SE. Another study investigating the
effects of LEV on visual-spatial memory following SE corroborated
these findings (32). Adult rats subjected to SE were treated first
with LEV or vehicle for 14 days, tested for visual-spatial memory
in the Morris water-maze and then used for unit recording in the
CA1 region of the hippocampus. Animals undergoing SE displayed
impaired learning and memory function in the water-maze test
and abnormalities in firing patterns of pyramidal neurons (place
cells) in the CA1 cell layer. LEV treatment had no major effects
on water-maze performance or place cell function. Histological
analyses however revealed severe neurodegeneration in the CA1
pyramidal cell layer of rats receiving vehicle after SE and relatively
reduced neurodegeneration in rats receiving LEV after SE.
Thus, the extent of neuroprotection mediated by LEV treatment
was not adequate for preventing SE-induced cognitive dysfunc-
tion. However, discrepancy in results between studies may reflect
differences in species and strains of animals examined, timing, and
dose of LEV treatment after SE, and severity of SE at the time of
commencement of LEV treatment. Timing of treatment after SE is
particularly important because a study using a rat perforant path-
way stimulation model has shown that administration of LEV
5 h after SE does not protect from mitochondrial dysfunction
but LEV treatment during established SE prevents mitochondrial
dysfunction (7, 33).
PROMISE OF LEV FOR MEDIATING NEUROPROTECTION
AGAINST TRAUMATIC BRAIN INJURY
Investigation of the effects of LEV in animal models of closed
head injury (CHI) and SAH suggested that LEV is neuroprotective
against traumatic brain injury (TBI) (6). In this study, a single
intravenous dose of LEV has been shown to improve both func-
tional and histological outcomes after CHI. Moreover, the ben-
eficial effects seemed specific for LEV treatment as fosphenytoin
administration did not result in such effects. Administration of
LEV also improved functional outcomes and reduced vasospasm
following SAH. This was the first study to suggest that LEV could be
a therapeutic alternative to phenytoin for TBI in clinical situations
where seizure prophylaxis drugs are indicated. Moreover, a recent
study has examined the effects of LEV on motor and cognitive
function in a rat prototype of TBI (2). Adult male rats were admin-
istered LEV (50 mg/kg, i.p) or vehicle daily for 20 days beginning
1 day following a controlled cortical impact (CCI) injury or sham
surgery. Animals were assessed for various behavioral tests, which
comprised assessment of motor function via beam walking test
and spatial learning and memory function through Y-maze and
Morris water-maze tests. The results showed that daily LEV treat-
ment for 20 days improved motor function and enhanced novel
arm exploration in the Y-maze. Furthermore, LEV treatment
promoted greater sparing of hippocampal neurons, decreased
contusion volumes, reversed TBI-induced decreases observed in
glutamate transporters and markers that promote neuroplasticity,
and reduced the expression of pro-inflammatory cytokine IL-1β.
However, LEV treatment did not improve spatial learning abil-
ity in rats with TBI. Collectively, these animal studies imply that
daily LEV treatment has favorable effects on structural, mole-
cular, and some of the behavioral components of neurological
improvements after TBI, likely through modulation of excitatory
and neuroinflammatory pathways (2).
Additionally, several clinical studies have ascertained the effi-
cacy of LEV for preventing PTS or post-traumatic epilepsy (PTE).
Amongst∼275,000 individuals who are typically hospitalized with
TBI every year, ∼7% experience PTS (34). As per guidelines of
the Brain Trauma Foundation and the American Academy of
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Neurology for the management of severe TBI, administration of
AEDs to prevent PTS is recommended only through the initial
7 days after TBI (34). Amid AEDs, the efficiency of phenytoin
treatment has been extensively examined for preventing PTS after
TBI. However, several clinical studies suggest that LEV treatment
after TBI is also effective for decreasing the predilection for devel-
oping PTS. Jones and colleagues analyzed EEG recordings from
patients receiving phenytoin or LEV for seizure prevention follow-
ing severe TBI (35). This comparative analysis revealed that LEV
is as efficient as phenytoin in averting early PTS but is allied with
an increased seizure predisposition based on evaluation of EEG
recordings. Another open label, non-randomized phase 2 study
assessed the safety, tolerability, and effectiveness of LEV therapy
in patients with TBI exhibiting greater susceptibility for PTE (36).
LEV treatment was initiated within 8 h after injury and contin-
ued for 30 days in this study. Two-year follow-up uncovered that
occurrence of PTE in patients receiving LEV (11%) is less than
that observed in untreated TBI patients (20%). However, several
recent clinical studies in TBI patients report that LEV does not
outperform phenytoin as a prophylaxis drug against PTS (37, 38).
Another recent clinical study has reported that LEV treatment to
children ages 6–17 years with risk factors for the development of
PTE decreased the incidence of PTE, as only 1 in 40 patients receiv-
ing LEV displayed PTE (39). Collectively, from the above studies,
it emerges that LEV has analogous ability as phenytoin for thwart-
ing PTS after TBI. It is also reported that LEV treatment for TBI
is linked with fewer adverse effects and monitoring considerations
[for details, see the review by Ref. (34)]. Nonetheless, because LEV
administration was accompanied by an increased seizure propen-
sity (35), the Brain Trauma Foundation has recommended using
phenytoin for early PTS prophylaxis (34).
LEV AS A NEUROPROTECTIVE COMPOUND AGAINST STROKE
Seizures following stroke is one of the causes of epilepsy in adults,
particularly in elderly patients (40). Seizures typically occur in
∼10% of stroke patients, depending on risk factors, such as the
type of stroke, location of stroke-induced damage in the brain, and
severity of the stroke (40). However, stroke accounts for∼50% of
seizures in individuals above the age of 65 years (41). Classically,
the use of AEDs to avert recurrent post-stroke seizures is recom-
mended. LEV has been suggested as a first-choice drug against
post-stroke seizures, based on safety and efficacy profiles in clini-
cal studies (42). Kutlu and colleagues examined the suitability of
LEV monotherapy in individuals aged 60 or older and exhibiting
a minimum of two late-onset post-stroke seizures (43). At daily
doses of 1000–2000 mg, they reported that 82.4% of the patients
were seizure free but seven patients (20.6%) had side effects.
These results suggested that LEV monotherapy is efficient and well
tolerated in elderly patients with late-onset post-stroke seizures.
Consoli and associates compared the efficacy of LEV treatment
with carbamazepine (CBZ) in patients with post-stroke seizures
in a multicenter randomized open label study (41). Evaluation of
results in 106 patients (52 treated with LEV and 54 treated with
CBZ) showed no noteworthy variance in the number of seizure
free patients between LEV and CBZ. Yet, interval to the first recur-
rence tended to be longer in patients receiving LEV. The results
also suggested that LEV treatment caused considerably less side
effects than CBZ, as attention deficit, frontal executive functions,
and functional scales (Activities of Daily Living and Instrumental
Activities of Daily Living indices) were notably poorer in patients
receiving CBZ (41).
Thus, studies conducted so far imply that LEV is a useful alter-
native to CBZ for post-stroke seizures, predominantly in terms
of efficacy and decreased adverse effects. However, another recent
study reported that LEV is not effective for the treatment of cen-
tral post-stroke pain, a severe chronic neuropathic pain state called
allodynia resulting from a vascular lesion (44). Considering these,
further studies are needed to ascertain the efficacy of LEV as a
suitable neuroprotective and seizure-preventing drug after stroke.
Additionally, rigorous studies in animal models of stroke are
needed to understand the potential anti-seizure, neuroprotective,
and anti-epileptogenic effects of LEV following stroke.
OVERALL CONCLUSION
From the analysis of literature pertaining to LEV treatment medi-
ated protection in neurological disorders, it emerges that LEV
treatment has potential for restraining SE-, TBI-, and stroke-
induced chronic epilepsy development. Particularly, LEV adminis-
tration has been found to be advantageous for restraining seizures
and/or seizure-induced neurodegeneration in animal models of
spontaneous epilepsy, acute seizures, and SE. LEV treatment
appears to mediate anti-seizure and neuroprotective effects via
modulation of Ca2+ currents in neurons, inhibition of the up-
regulation of brain-derived neurotrophic factor, increases in NPY
receptors, and antioxidant proteins, and decreases in pro-oxidant
proteins (14, 15, 17). Nonetheless, the capability of LEV for easing
epileptogenesis and cognitive dysfunction following SE remains
contentious. Several studies report promising outcomes such as
delayed development of hippocampal hyperexcitability, restraint
of electrographic seizures, diminishment in the abnormal migra-
tion of newly born neurons into the dentate hilus, and inhibition
of inflammatory responses in SE models (20, 26, 27, 29). There are
also reports of mitigation of synaptic potentiation and abnormal
expression of IEGs, and prevention of abnormal accumulation
of 7S SNARE complexes and SV2 in kindling models (15, 22–
24). However, some studies report no beneficial effects of LEV
treatment after SE in terms of easing epileptogenesis or cognitive
dysfunction (31, 32). Discrepancy in the findings between stud-
ies may reflect differences in the timing of intervention with LEV,
doses of LEV employed and severity of SE at the time of initial
intervention with LEV.
The efficiency of LEV as a neuroprotective drug against TBI
has received much consideration. Animal studies in TBI models
validate greater sparing of hippocampal neurons, and improved
motor and memory function with LEV treatment (2, 6). On the
other hand, results of several recent clinical trials convey that
LEV has comparable efficacy as phenytoin in terms of its abil-
ity for preventing PTE (34, 37–39). The other positive effects of
LEV treatment for TBI comprise fewer adverse effects and mon-
itoring issues. However, one caveat of LEV treatment for TBI is
the presence of increased seizure propensity in long-term EEG
recordings (34, 35). Studies on stroke imply that LEV is a useful
alternative to CBZ for preventing post-stroke seizures including
elderly patients, in terms of efficacy and safety (40–43) but does
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not seem to be useful for easing central post-stroke pain (44).
Taken together, studies conducted so far suggest that LEV treat-
ment is useful for easing SE-, TBI-, and stroke-induced chronic
epilepsy development. Nevertheless, rigorous additional studies
in animal models are needed to ascertain the most beneficial dose,
timing of intervention, and duration of treatment after the initial
precipitating injury and mechanisms underlying LEV-mediated
beneficial effects on epileptogenesis.
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